BioTech IQ
  • Home
  • Podcast
  • Hiring?
  • Blog
  • Contact
Select Page
Qualigen Therapeutics: Where It All Started And Where It’s Going With Founder And CEO Michael Poirier

Qualigen Therapeutics: Where It All Started And Where It’s Going With Founder And CEO Michael Poirier

by Ammon Rivera | Oct 8, 2022 | Podcast

  In this episode of BioTech IQ, Ammon Rivera continues his exploration of Qualigen Therapeutics by interviewing the founder and CEO of the company Michael Porier. Michael discusses how Qualigen was started and the motivation behind the therapeutics pipeline....
Harnessing the Innate Immune System By Developing Three Types of iPSC-Derived Natural Killer Cells With Daniel Teper

Harnessing the Innate Immune System By Developing Three Types of iPSC-Derived Natural Killer Cells With Daniel Teper

by Ammon Rivera | Jul 15, 2022 | Podcast

  Companies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology...

Recent Posts

  • Biotech Chief People Officer Discusses How To Build Company Culture
  • Qualigen Therapeutics: Where It All Started And Where It’s Going With Founder And CEO Michael Poirier
  • Qualigen Therapeutics: How To Develop An Oncology Therapeutics Pipeline From A CMO’s Perspective With Tariq Arshad, MD
  • Qualigen Therapeutics: How Do You Develop A Successful Therapeutics Pipeline In Oncology With Amy Broidrick
  • Mapping The Human Immune System: Using AI To Change Drug Development With Noam Solomon

Recent Comments

  1. Ammon Rivera on Can Lineage Cell Therapeutics Proprietary Cell-Based Therapy Platform Change Treatment Development?
  2. Andy blidy on Can Lineage Cell Therapeutics Proprietary Cell-Based Therapy Platform Change Treatment Development?

Follow BioTech IQ 

  • Follow
  • Follow
  • Follow
biotech logo black

187 W Main St,
Suite 203
Lehi, UT 84043

Biotech IQ © Copyright 2022. All Rights Reserved